Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TTX MC 138

Next Previous
Drug Profile

TTX MC 138

Alternative Names: TTX-MC-138

Latest Information Update: 10 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TransCode Therapeutics
  • Class Antineoplastics; Antisense oligonucleotides; Immunotherapies
  • Mechanism of Action Cell death stimulants; Gene silencing; MicroRNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I/II Solid tumours
  • Preclinical Glioblastoma; Osteosarcoma; Pancreatic cancer; Small cell lung cancer; Triple negative breast cancer; Unspecified

Most Recent Events

  • 03 Jun 2026 Efficacy and adverse events data from a phase I/II trial in Solid tumours released by TransCode Therapeutics
  • 27 May 2026 Phase-II clinical trials in Colorectal cancer (Second-line therapy or greater) (IV)
  • 27 Apr 2026 TransCode Therapeutics enters into a sponsored research agreement (SRA) with Michigan State University to develop TTX M 138 in combination with seviprotimut-L

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top